Rightslink® by Copyright Clearance Center

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Author:

Christoph Röllig,Hubert Serve,Andreas Hüttmann,Richard Noppeney,Carsten Müller-Tidow,Utz Krug,Claudia D Baldus,Christian H Brandts,Volker Kunzmann,Hermann Einsele,Alwin Krämer,Kerstin Schäfer-Eckart,Andreas Neubauer,Andreas Burchert et al.

Publication:

The Lancet Oncology

Publisher:

Elsevier

Date:

December 2015

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Welcome to RightsLink

Elsevier has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing this content.

I would like to...This drop down menu contains the options the publisher has agreed to permit for reuse of their copyrighted material. The publisher offers these types of use either directly through RightsLink or after approval by the publisher. Please reference the terms and conditions offered during the order process for a complete understanding of the use you select. Need more info?